Valuation: Senzime AB

Market Cap 628M 65.65M 56.9M 53.34M 48.64M 91.52M 6.27B 92.98M 245M 3.14B 246M 241M 10.46B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 628M 65.65M 56.9M 53.34M 48.64M 91.52M 6.27B 92.98M 245M 3.14B 246M 241M 10.46B EV / Sales 2026 *
4.92x
EV / Sales 2027 * 3.08x
Free-Float
40.74%
Yield 2026 *
-
Yield 2027 * -
1 day+16.95%
1 week+76.92%
Current month+86.79%
1 month+45.72%
3 months+44.59%
6 months+11.74%
Current year+27.28%
1 month 0.37
Extreme 0.3694
0.69
Current year 0.37
Extreme 0.3694
0.69
1 year 0.37
Extreme 0.3694
0.72
3 years 0.37
Extreme 0.3694
0.96
5 years 0.25
Extreme 0.251
2.45
10 years 0.25
Extreme 0.251
3
Manager TitleAgeSince
Chief Executive Officer 53 03/05/2023
Director of Finance/CFO 56 01/01/2022
Chief Tech/Sci/R&D Officer 50 01/01/2023
Director TitleAgeSince
Chairman 53 03/05/2023
Director/Board Member 70 01/01/2016
Director/Board Member 63 05/03/2020
Change 5-day change 1-year change 3-year change Capi.($)
+16.95%+76.92% - - 64.63M
+0.32%+3.07%-14.01%+5.66% 192B
-0.20%+5.42%-2.51%+8.54% 116B
-1.32%-4.62%+6.52%+65.45% 59.95B
-0.21%+3.33%+37.64%+64.21% 54.64B
-0.88%+2.77%-7.14%-35.54% 50B
+0.75%+10.19%+14.41%-18.09% 34.26B
+0.23%+3.10% - - 31.15B
-1.74%-0.70%+40.59%-12.31% 24.79B
+1.70%+12.43%-2.96%+25.70% 24.07B
Average +1.57%+3.69%+9.07%+12.95% 65.22B
Weighted average by Cap. -0.11%+3.17%+0.97%+13.36%

Financials

2026 *2027 *
Net sales 128M 13.35M 11.57M 10.85M 9.89M 18.61M 1.27B 18.9M 49.85M 638M 50.11M 49.02M 2.13B 204M 21.32M 18.48M 17.33M 15.8M 29.72M 2.03B 30.2M 79.64M 1.02B 80.05M 78.32M 3.4B
Net income -68.9M -7.2M -6.24M -5.85M -5.34M -10.04M -687M -10.2M -26.9M -344M -27.04M -26.45M -1.15B -36.8M -3.85M -3.33M -3.13M -2.85M -5.36M -367M -5.45M -14.37M -184M -14.44M -14.13M -613M
Net Debt - -
Logo Senzime AB
Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Employees
59
Date Price Change Volume

Quarterly revenue - Rate of surprise